Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | TACR2 | P21452 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270236 | 1.00 | PTGER2 (0.40) | PTGER2SPHK1PTGS2CYP3A4CYP19A1 | |
| SCHEMBL7106410 | 1.00 | PTGER2 (0.40) | PTGER2SPHK1PTGS2CYP3A4CYP19A1 | |
| SCHEMBL7112580 | 0.98 | PTGER2 (0.42) | PTGER2SPHK1PTGS2CYP3A4CYP19A1 | |
| SCHEMBL6560473 | 0.89 | PTGER2 (0.36) | PTGER2SPHK1PTGS2CYP3A4CYP19A1 | |
| SCHEMBL9250719 | 0.77 | — | — | |
| SCHEMBL7156105 | 0.77 | PTGER2 (0.38) | PTGER2SPHK1PTGS2CYP3A4 | |
| SCHEMBL5964829 | 0.75 | PTGER2 (0.45) | PTGER2ALDH1A1 | |
| SCHEMBL6538198 | 0.74 | — | — | |
| SCHEMBL23924389 | 0.73 | — | — | |
| SCHEMBL2302603 | 0.73 | PTGER2 (0.36) | PTGER2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478217-A | Preparation method of 2-n-pentylcyclopent-2-enone | 山东新和成药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210324297-A1 | CYCLIC OXY ETHER COMPOUNDS AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2021-10-21 | — | — | US | disclosed |
| WO-2011101757-A1 | CYCLIC OXY COMPOUNDS AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101757-A1 | CYCLIC OXY COMPOUNDS AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 2011-08-25 | — | — | WO | disclosed |
| EP-1048643-B1 | Process for the preparation of chiral epoxides | FIRMENICH & CIE (CH) | 2003-10-22 | — | — | EP | disclosed |
| US-6573395-B2 | Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine)) | FIRMENICH SA (CH) | 2003-06-03 | — | — | US | disclosed |
| EP-1012131-B1 | ENANTIOSELECTIVE REDUCTION OF KETONES WITH A SILANE AGENT/METAL COMPOUND/CHIRAL LIGAND SYSTEM | FIRMENICH & CIE (CH) | 2003-03-19 | — | — | EP | disclosed |
| US-20020161252-A1 | Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine)) | FIRMENICH SA, A SWISS COMPANY | 2002-10-31 | — | — | US | disclosed |
| US-6392103-B1 | USING ORGANOMETALLIC COMPOUND AS CATALYST | FIRMENICH SA (CH) | 2002-05-21 | — | — | US | disclosed |
| US-6262288-B1 | Process for the preparation of chiral epoxides | FIRMENICH SA (CH) | 2001-07-17 | — | — | US | disclosed |
| EP-1048643-A1 | Process for the preparation of chiral epoxides | FIRMENICH SA (CH) | 2000-11-02 | — | — | EP | disclosed |
| EP-1012131-A1 | ENANTIOSELECTIVE REDUCTION OF KETONES WITH A SILANE AGENT/METAL COMPOUND/CHIRAL LIGAND SYSTEM | FIRMENICH SA (CH) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999012877-A1 | ENANTIOSELECTIVE REDUCTION OF KETONES WITH A SILANE AGENT/METAL COMPOUND/CHIRAL LIGAND SYSTEM | FIRMENICH S.A. (CH) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161252-A1 | Zinc complex with a chiral ligand, such as diethylzinc((S,S)-N-N'-ethylene-bis-(1-phenylethylamine)) | ERH, POLH, PNMT | PTGER2 2465/4885SPHK1 753/4885PTGS2 3464/4885 |
| US-20210324297-A1 | CYCLIC OXY ETHER COMPOUNDS AS PERFUMING INGREDIENTS | CBR3, CYP2E1, CBR1 | PTGER2 143/4885SPHK1 1713/4885PTGS2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.